Literature DB >> 9063680

Economic aspects of treatment for fungal infections in cancer patients.

K Torfs1.   

Abstract

Although health care expenditure has increased steadily over the past decennium, the general feeling is that resources are more limited than ever. One reason for this may be that the range of treatment options has grown so wide that the need to make rational choices has become apparent. Since treatments vary with respect to both effectiveness and cost, economic evaluations are becoming an important tool for assessing new and existing treatment strategies. The basic concepts of economic evaluation will be introduced here and the key economic questions with respect to treatment of fungal infections in cancer patients identified. Some of these concepts are explained using findings from a pilot survey carried out among participants in the symposium "Trends in Invasive Fungal Infections-3" 7-9 held September, 1995, in Brussels, Belgium. The conclusion will offer recommendations for assessing economic evaluations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9063680     DOI: 10.1007/bf01575127

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

2.  Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses.

Authors:  U Persson; G R Tennvall; S Andersson; G Tyden; B Wettermark
Journal:  Pharmacoeconomics       Date:  1992-12       Impact factor: 4.981

3.  Costs of antifungal prophylaxis after bone marrow transplantation. A model comparing oral fluconazole, liposomal amphotericin and oral polyenes as prophylaxis against oropharyngeal infections.

Authors:  A Stewart; R Powles; M Hewetson; J Antrum; C Richardson; J Mehta
Journal:  Pharmacoeconomics       Date:  1995-10       Impact factor: 4.981

4.  Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology.

Authors: 
Journal:  Ann Intern Med       Date:  1995-07-01       Impact factor: 25.391

Review 5.  Sensitivity analysis in economic evaluation: a review of published studies.

Authors:  A Briggs; M Sculpher
Journal:  Health Econ       Date:  1995 Sep-Oct       Impact factor: 3.046

Review 6.  New methods of delivery of amphotericin B.

Authors:  H J Schmitt
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

7.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

Authors:  J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

Review 8.  Clinical use of liposomal and lipid-complexed amphotericin B.

Authors:  S de Marie; R Janknegt; I A Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

9.  Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

Authors:  D J Winston; P H Chandrasekar; H M Lazarus; J L Goodman; J L Silber; H Horowitz; R K Shadduck; C S Rosenfeld; W G Ho; M Z Islam; D N Buell
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

Review 10.  European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care.

Authors:  C Williams; D Coyle; A Gray; J Hutton; T Jefferson; G Karlsson; K Kesteloot; C Uyl-de Groot; S Wait
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

  10 in total
  4 in total

Review 1.  The cost of treating systemic fungal infections.

Authors:  R van Gool
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  [Anti-fungal drugs. Current status and guidelines for their administration].

Authors:  Rodrigo Fernández Alonso; Maria Esther González García; Joaquín Fernández García; Francisco Javier Cepeda Piorno
Journal:  Clin Transl Oncol       Date:  2005-10       Impact factor: 3.405

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.

Authors:  Robin de Vries; Simon Daenen; Keith Tolley; Axel Glasmacher; Archie Prentice; Sarah Howells; Hariette Christopherson; Lolkje T W de Jong-van den Berg; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.